Search results

• Active

  22-LEUK-21-NP (CABL001AUS08): A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase-Chronic Myelogenous Leukemia (ASC2ESCALATE)

  Munker, R.

  Novartis (domestic)

  2/3/23 → 12/13/23

  Project: Research project

• 22-HEM-19-MSD: A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-Refractory, Relapsed or Refractory Classical Hodgkin Lymphoma

  Munker, R.

  Merck Sharp & Dohme Corporation

  1/23/23 → 11/2/23

  Project: Research project

• A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naive Mantle Cell Lymphoma (BRUIN MCL-321)

  Munker, R.

  IQVIA RDS Incorporated

  9/29/21 → 6/28/23

  Project: Research project

• Phase III, Multi-Center, Open-Label, Randomized Study Of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia In Chronic Phase

  Munker, R.

  Novartis (domestic)

  8/17/21 → 10/30/23

  Project: Research project

• Finished

  A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  Munker, R.

  IQVIA RDS Incorporated

  8/31/21 → 4/24/23

  Project: Research project

• An Open Label, Multi-Center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

  Munker, R.

  Novartis (domestic)

  7/15/21 → 4/19/23

  Project: Research project

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

  Munker, R.

  Incyte Corporation

  5/13/21 → 4/24/23

  Project: Research project

• A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)

  Munker, R.

  AbbVie Incorporated

  6/10/20 → 5/12/21

  Project: Research project